Cessation of Therapy with Atenolol
Patients with coronary artery disease, who are being treated with atenolol, should be advised against abrupt discontinuation of therapy. Severe exacerbation of angina and the occurrence of myocardial infarction and ventricular arrhythmias have been reported in angina patients following the abrupt discontinuation of therapy with beta-blockers. The last two complications may occur with or without preceding exacerbation of the angina pectoris. As with other beta-blockers, when discontinuation of atenolol is planned, the patients should be carefully observed and advised to limit physical activity to a minimum. If the angina worsens or acute coronary insufficiency develops, it is recommended that atenolol be promptly reinstituted, at least temporarily. Because coronary artery disease is common and may be unrecognized, it may be prudent not to discontinue atenolol therapy abruptly even in patients treated only for hypertension (see
DOSAGE AND ADMINISTRATION).
Atenolol, a synthetic, beta1-selective (cardioselective) adrenoreceptor blocking agent.
Atenolol tablets, USP are indicated in the management of hypertension. It may be used alone or concomitantly with other antihypertensive agents, particularly with a thiazide-type diuretic.
Angina Pectoris Due to Coronary Atherosclerosis
Atenolol tablets, USP are indicated for the long-term management of patients with angina pectoris.
Acute Myocardial Infarction
Atenolol tablets, USP are indicated in the management of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality. Treatment can be initiated as soon as the patients clinical condition allows (see
DOSAGE AND ADMINISTRATION, CONTRAINDICATIONS, and
WARNINGS). In general, there is no basis for treating patients like those who were excluded from the ISIS-1 trial (blood pressure less than 100 mm Hg systolic, heart rate less than 50 bpm) or have other reasons to avoid beta-blockade. As noted above, some subgroups (e.g., elderly patients with systolic blood pressure below 120 mm Hg) seemed less likely to benefit.
Published Studies Related to Atenolol
Identifying iatrogenic depression using confirmatory factor analysis of the Center for Epidemiologic Studies Depression Scale in patients prescribed a verapamil-sustained-release-led or atenolol-led hypertension treatment strategy. [2011.11.29]
BACKGROUND: beta-blockers and calcium channel blockers are highly effective medications indicated for treatment and prevention of hypertension. However, the literature regarding the potential depressive effects of beta-blockers and calcium channel blockers is equivocal regarding whether one or both are associated with depression. OBJECTIVES: To determine whether self-reported depressive symptoms of older persons with hypertension and coronary artery disease and who were randomly assigned to a verapamil-sustained-release-led (Ve-led) or atenolol-led (At-led) hypertension treatment strategy were similar using confirmatory factor analytical models of the Center for Epidemiologic Studies Depression Scale (CES-D)... CONCLUSIONS: The domains indicating less happiness and more depressive symptoms were most likely to be unfavorably impacted by the At-led treatment strategy. Given a choice between these equally effective high blood pressure treatment strategies, it may be prudent to use the Ve-led strategy. This is especially true if the risk of the occurrence of a mood-related side effect of the beta-blocker outweighs its other benefits in comparison. Copyright (c) 2011 Elsevier Inc. All rights reserved.
[Study of the efficacy and safety of losartan versus atenolol for aortic dilation in patients with Marfan syndrome]. [2011.06]
INTRODUCTION AND OBJECTIVES: Marfan syndrome is an inherited disease of the connective tissue. Recent trials have indicated the use of losartan (a transforming growth factor beta inhibitor) in these patients prevents aortic root enlargement. The aim of our clinical trial is to assess the efficacy and safety of losartan versus atenolol in the prevention of progressive dilation of the aorta in patients with Marfan syndrome... CONCLUSIONS: Efficacy of losartan versus atenolol in the prevention of progressive dilation of the aorta, improved aortic distensibility, and prevention of adverse events (aortic dissection or rupture, cardiovascular surgery, or death) will be assessed in this study. It will also show the possible treatment benefits at different age ranges and with relation to the initial level of aortic root dilation. Copyright (c) 2011 Sociedad Espanola de Cardiologia. Published by Elsevier Espana. All rights reserved.
Comparison of the effects of ivabradine and atenolol on heart rate and echocardiographic variables of left heart function in healthy cats. [2011.05]
BACKGROUND: Ivabradine is a novel negative chronotropic drug used for treatment of ischemic heart disease in people. Little is known about its effects and safety in cats.Clinical studies in cats with hypertrophic cardiomyopathy are needed to validate these findings.
Effect of atenolol vs metoprolol succinate on vascular function in patients with hypertension. [2011.01]
BACKGROUND: We evaluated the effect of atenolol vs metoprolol succinate on vascular function in patients with essential hypertension. HYPOTHESIS: Given intrinsic differences between these agents, we hypothesized that atenolol and metoprolol succinate would have disparate effects on vascular function... CONCLUSIONS: Although atenolol and metoprolol succinate have similar effects on blood-pressure reduction, they have different effects on vascular function. Compared with metoprolol succinate, atenolol increases peripheral AIx. Neither drug has an effect on vascular endothelial function. These findings may have clinical implications, depending on the indication for treatment in an individual patient. (c) 2011 Wiley Periodicals, Inc.
beta(1)-Adrenergic receptor gene polymorphisms and the acute response to atenolol in healthy young Japanese subjects. 
Polymorphisms at codons 49 and 389 of the beta(1)-adrenergic receptor gene have been shown to alter the receptor function in vitro, whereas it remains controversial whether they influence the response to beta-blocker in vivo. In the present study, we investigated whether these polymorphisms influence the acute changes of heart rate and blood pressure induced by the beta(1)-adrenergic receptor-selective blocker atenolol in healthy young Japanese...
Clinical Trials Related to Atenolol
Effects of Losartan Versus Atenolol on Aortic and Cardiac Muscle Stiffness in Adults With Marfan Syndrome [Completed]
Marfan syndrome is an inherited connective tissue disorder with morbidity and mortality from
aortic dilation and dissection. The degree of aortic dilation and response to beta-blockade
(standard of care) vary in adults with Marfan syndrome. However, aortic stiffness is often
present, and can be a predictor of aortic dilation and cardiovascular complications. In
addition, adults with Marfan syndrome develop left ventricular diastolic dysfunction, which
can progress to heart failure. Aortic stiffness and diastolic dysfunction are important and
logical therapeutic targets in adults with Marfan syndrome.
TGF-beta mediates disease pathogenesis in Marfan syndrome and contributes to aortic
stiffness. The angiotensin receptor blocker, losartan, inhibits TGF-beta activity and
reverses aortic wall pathology in a Marfan mouse model. Losartan also decreases aortic
stiffness and improves diastolic function in hypertension, renal disease and hypertrophic
This trial is a randomized, double-blind trial of 50 adults with Marfan syndrome, treated
with 6 months of atenolol vs. losartan. Arterial tonometry for aortic stiffness and
echocardiography for diastolic function will be performed at the beginning and end of
treatment. A blood draw for serum markers of extracellular matrix turnover and inflammation
will also be performed at 0 and 6 months. We plan to determine whether losartan decreases
aortic stiffness and left ventricular diastolic dysfunction significantly more than
Effect of SLCO2B1 Genotype and Apple Juice on Pharmacokinetics of Atenolol After Oral Administration in Healthy Male Korean [Completed]
Atenolol Versus Losartan in the Prevention of Progressive Dilation of the Aorta in Marfan Syndrome [Active, not recruiting]
The purpose of this study is to evaluate the efficacy of Losartan versus Atenolol in the
progression of aortic dilatation in patients with Marfan syndrome.
Study to Assess Efficacy of Nicorandil+Atenolol vs Atenolol in Treatment of Chronic Stable Angina. [Recruiting]
Safety and Efficacy of Valsartan vs Atenolol and Hydrochlorothiazide Combination on Blood Flow in Hypertensive Patients [Completed]
This study evaluated the effect of valsartan on small vessel blood flow in patients with
mild-to-moderate hypertension in direct comparison to atenolol and hydrochlorothiazide.
Reports of Suspected Atenolol Side Effects
Completed Suicide (151),
Toxicity TO Various Agents (65),
Blood Pressure Increased (62),
Drug Ineffective (51),
Cardiac Arrest (46),
Renal Failure Acute (44),
Dizziness (42), more >>
PATIENT REVIEWS / RATINGS / COMMENTS
Based on a total of 12 ratings/reviews, Atenolol has an overall score of 8. The effectiveness score is 8 and the side effect score is 7.83. The scores are on ten point scale: 10 - best, 1 - worst. Below are selected reviews: the highest, the median and the lowest rated.
Atenolol review by 60 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Highly Effective|
|Side effects:|| || No Side Effects|
|Condition / reason:|| || Extra Heartbeat|
|Dosage & duration:|| || 25 mg/day taken 1 /day for the period of 13+ years|
|Other conditions:|| || None|
|Other drugs taken:|| || None|
|Benefits:|| || The benefits are amazing. I felt dizzy and like I was going to faint before I took the drug. These symptoms went away and have stayed away for going on 20 years. I also have seen that it helps with blood pressure and pulse rate. |
|Side effects:|| || I have never experienced any adverse side affects.|
|Comments:|| || I simply take one tiny tablet each morning.|
Atenolol review by 67 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Moderately Effective|
|Side effects:|| || Mild Side Effects|
|Condition / reason:|| || hypertension|
|Dosage & duration:|| || 25 mg taken 1 po qd for the period of 3 years|
|Other conditions:|| || none|
|Other drugs taken:|| || none|
|Benefits:|| || Effective in reducing hypertension from previous approximately 170/85 to less than 150/65 and now even less at approximately 130/65|
|Side effects:|| || Side effected included sleepiness, and unaccountably nausea while sailing. Prior to taking this drug I had never had problems with "seasickness" while sailing. I found I had to stay topside during sailing times. Other than that, the tiredness was a factor which became less noticeable with time. The seasickness would not be a problem for the majority of people, I am sure|
|Comments:|| || Treatment was 1 pill per day for approximately 3 years (25 mg) which I am told is a quite low dose for this medication. However my weight is 100 lbs on average and small build so for me it was more than enough. It helped my hypertension come back to within normal range which I was pleased with. If I needed to go back on an antihypertensive, I would try it again |
Atenolol review by 62 year old male patient
|Overall rating:|| || |
|Effectiveness:|| || Ineffective|
|Side effects:|| || Severe Side Effects|
|Condition / reason:|| || Atrial Fibrillation|
|Dosage & duration:|| || 25 mg taken daily for the period of 3 months|
|Other conditions:|| || mild hypertension|
|Other drugs taken:|| || warafin, lisinopril|
|Benefits:|| || none except....slowed heart rate. My afib was NOT diminished, but I assume the drug was helping keep my heart rate when in Afib down somewhat|
|Side effects:|| || The 3 months i was on atenolol (25mg) I had vertigo, short term memory loss, anxiety, and hearing issue. All except hearing went away when I switched to a different beta blocker.
|Comments:|| || once a day 25 mg|
Page last updated: 2011-12-09